US Broker Ratings

GoodRx Holdings Inc. (GDRX) Stock Analysis: Assessing a Potential 76.84% Upside in Health Information Services

GoodRx Holdings, Inc. (NASDAQ: GDRX) represents a unique player in the healthcare sector, particularly within the Health Information Services industry. As a company providing consumers with the ability to compare..

MannKind Corporation (MNKD) Stock Analysis: Unpacking an 84.47% Potential Upside Amid Biotech Innovation

MannKind Corporation (NASDAQ: MNKD) has carved a niche in the healthcare sector, with a focus on developing and commercializing therapeutic products for endocrine and orphan lung diseases. Based in Danbury,..

Dynavax Technologies Corporation (DVAX) Stock Analysis: Exploring a 40.75% Potential Upside

Dynavax Technologies Corporation (NASDAQ: DVAX) is a prominent player in the healthcare sector, specifically within the drug manufacturing industry, focusing on specialty and generic products. Based in the United States,..

Omnicell, Inc. (OMCL) Stock Analysis: Exploring an 8.87% Potential Upside in the Healthcare Sector

Omnicell, Inc. (NASDAQ: OMCL) is a noteworthy player in the healthcare sector, specifically within the health information services industry. With a market capitalization of $2.32 billion, Omnicell is making strides..

Harrow, Inc. (HROW) Stock Analysis: A Strong Buy with 47.44% Potential Upside

Investors interested in Harrow, Inc. (NASDAQ: HROW) will find plenty to be optimistic about as the company positions itself as a formidable player in the healthcare sector. Specializing in the..

Pulse Biosciences, Inc (PLSE) Investor Outlook: Exploring a 54% Potential Upside

Pulse Biosciences, Inc (NASDAQ: PLSE) is capturing the attention of investors with its innovative approach to bioelectric medicine. Operating within the healthcare sector and specializing in medical instruments and supplies,..

Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: A Biotech with 55.39% Potential Upside

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) is making waves in the biotechnology sector, driven by its innovative approach to tackling diseases associated with dysregulated aldosterone. With a market capitalization of $2.59..

Artivion, Inc. (AORT) Stock Analysis: Unlocking a Potential 19% Upside in the Medical Devices Sector

Artivion, Inc. (NASDAQ: AORT), a prominent player in the healthcare sector, specifically within the medical devices industry, is catching the attention of investors with a compelling potential upside of 19.18%...

UFP Technologies (UFPT) Stock Analysis: Exploring a 26% Potential Upside in the Booming Medical Devices Sector

UFP Technologies, Inc. (NASDAQ: UFPT), a key player in the healthcare sector specializing in medical devices, has caught the attention of investors with a promising potential upside of 26.48%. With..

Phreesia, Inc. (PHR) Stock Analysis: Strong Buy Ratings and a 77.90% Potential Upside

Phreesia, Inc. (PHR), a prominent player in the healthcare sector, offers investors a compelling proposition with its integrated SaaS-based software and payment platform tailored for the healthcare industry across the..

ANI Pharmaceuticals, Inc. (ANIP): Investor Outlook with a Promising 30% Upside Potential

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) stands out as a promising player in the healthcare sector, particularly within the specialty and generic drug manufacturing industry. With a market capitalization of $1.91..

Biohaven Ltd. (BHVN) Stock Analysis: Exploring the 51.7% Potential Upside in Biotech

Biohaven Ltd. (BHVN) has been catching the eye of investors in the biotech sector, not least because of its substantial 51.7% potential upside according to analyst targets. With a market..

MiMedx Group, Inc (MDXG) Stock Analysis: Unlocking a Potential 117% Upside in the Biotech Sector

MiMedx Group, Inc. (NASDAQ: MDXG) stands at a pivotal point for investors seeking to capitalize on the burgeoning biotech sector. Specializing in the development and distribution of placental tissue allografts,..

Recursion Pharmaceuticals (RXRX) Investor Outlook: Unveiling a 49.89% Potential Upside in Biotechnology

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), a clinical-stage biotechnology company, is making waves in the healthcare sector with its innovative approach to drug discovery. Leveraging a blend of biology, chemistry, automation,..

Teladoc Health, Inc. (TDOC) Stock Analysis: Exploring a Potential 43.60% Upside in Virtual Healthcare

In the ever-evolving landscape of healthcare, Teladoc Health, Inc. (NYSE: TDOC) stands as a prominent player, offering a comprehensive suite of virtual healthcare services. With a market capitalization of $1.11..

Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Strong Buy Ratings Signal Potential 17% Upside

Protagonist Therapeutics, Inc. (NASDAQ: PTGX), a biotechnology company at the forefront of peptide therapeutics, is garnering significant attention from investors and analysts alike. With a market capitalization of $5.13 billion,..

10x Genomics, Inc. (TXG) Stock Analysis: Navigating Healthcare Innovation Amidst Market Challenges

10x Genomics, Inc. (NASDAQ: TXG), a pioneering force within the healthcare sector, has carved a niche in the health information services industry. With its headquarters in Pleasanton, California, the company..

BGM Group Ltd. (BGM) Stock Analysis: Navigating Challenges in the Healthcare Sector

For individual investors eyeing opportunities in the healthcare sector, BGM Group Ltd. (BGM) presents a complex yet intriguing case. Based in Chengdu, China, BGM operates within the intricate domain of..

Amphastar Pharmaceuticals, Inc. (AMPH) Stock Analysis: Exploring a 21% Potential Upside for Investors

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH), a distinguished player in the healthcare sector, is capturing investor attention with its unique blend of generic and proprietary injectable, inhalation, and intranasal products. Operating..

Pacira BioSciences, Inc. (PCRX) Investor Outlook: Exploring a 55% Potential Upside

Pacira BioSciences, Inc. (NASDAQ: PCRX), a prominent player in the healthcare sector specializing in non-opioid pain management solutions, presents an intriguing opportunity for investors. With a market capitalization of $824.29..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds